GenNext Technologies

Executive Summary

GenNext Technologies is a Boston-based structural biology company pioneering the Fox® Protein Footprinting technology, which uses hydroxyl radicals to probe solvent accessibility of amino acid side chains in proteins. This state-of-the-art approach enables high-resolution analysis of protein higher-order structure and dynamics, addressing critical needs in drug discovery and biopharmaceutical development. Founded in 2016 and currently at the pre-clinical stage, the company is positioning its platform to accelerate protein therapeutic development and quality control. With no disclosed funding or valuation, GenNext appears to be operating in stealth or early development. The technology's applicability across biologics, including monoclonal antibodies and complex protein therapeutics, offers significant market potential. However, as a private, pre-clinical company, it faces typical risks of technology validation and commercial adoption.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q4 2026Partnership with Major Pharma for Protein Characterization40% success
• Q2 2026Peer-Reviewed Publication Demonstrating Platform Utility75% success